Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?
Canadian Rheumatology Today · 2024
DOI: 10.58931/crt.2024.1252 ↗Kurz gefasst
Fachartikel in der Zeitschrift Canadian Rheumatology Today, 2024. Verfasst von Sherry Rohekar. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
As 2024 continues to evolve, so do treatment recommendations for the management of spondyloarthritis (SpA), including ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). From a Canadian perspective, we eagerly await the publication of the Canadian Rheumatology Association (CRA)/Spondyloarthritis Research Consortium of Canada (SPARCC) Living Treatment Recommendations for the Management of Axial Spondyloarthritis (axSpA), currently in press. Until these recommendations for axSpA treatment with a Canadian perspective arrive – where are we now?
Zitieren
APA
Rohekar, S. (2024). Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?. Canadian Rheumatology Today. https://doi.org/10.58931/crt.2024.1252
Vancouver
Rohekar S. Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?. Canadian Rheumatology Today. 2024. doi:10.58931/crt.2024.1252
BibTeX
@article{Rohekar2024,
author = {Rohekar, Sherry},
title = {Axial Spondyloarthritis Treatment Recommendations in 2024: Where Are We Now?},
journal = {Canadian Rheumatology Today},
year = {2024},
doi = {10.58931/crt.2024.1252}
}
EUVIMED